Opportunities for Capricor Shareholders to Pursue Securities Fraud Litigation

Investors Have a New Opportunity

Capricor Therapeutics, Inc., represented by Glancy Prongay Wolke & Rotter LLP, is currently facing a significant securities fraud class action lawsuit. This serves as a critical update for investors who suffered losses while trading shares of the company during the class period from December 17, 2025, to July 26, 2026.

The Allegations

The foundation of the lawsuit hinges on allegations that Capricor and its executives made materially false and misleading statements concerning the company's health and operational capabilities, particularly regarding the drug Deramiocel, intended for treating Duchenne muscular dystrophy (DMD). According to the lawsuit, the defendants failed to fully disclose crucial changes to the statistical analysis plan employed for interpreting clinical data related to Deramiocel. They allegedly did not seek the FDA's approval before resubmitting the Biologics License Application (BLA), which significantly raises concerns about the efficacy of Deramiocel and potential regulatory approval.

These actions have drawn the ire of investors who now feel deceived by the overwhelmingly positive portrayals offered by the company, only to later discover that the stated prospects lacked substantial backing. Investors are now poised to respond.

The Next Steps in The Legal Proceedings

Investors who were impacted must act promptly. Glancy Prongay Wolke & Rotter LLP emphasizes that those interested in leading the charge as plaintiffs must file their motions by September 28, 2026, which marks the final opportunity to take proactive measures in this litigation.

Potential class members who might have acquired Capricor securities during the specified time span need to consider whether they wish to join as lead plaintiffs. For those uncertain about the process or looking for legal counsel, the firm is readily available to assist with inquiries via email or telephone.

Why Choose Glancy Prongay Wolke & Rotter LLP?

Glancy Prongay Wolke & Rotter LLP stands as a well-respected legal entity, recognized for its extensive experience in securities litigation. The firm's accomplishments in advocating for investors have earned it a prestigious status, including recognition from Law360 as one of the top Securities Groups of the Year. GPWR's past cases span numerous industries, showcasing a breadth of expertise that positions them favorably in navigating complex investor claims.

This lawsuit cannot only provide a path for restitution to affected shareholders, but it also serves as a reminder for corporate accountability within the healthcare sector. The ramifications of such litigation may extend beyond monetary recoveries, potentially influencing regulatory practices and corporate governance standards within the biotechnology field.

Conclusion

For those impacted, now is an opportune moment to consider joining the class-action lawsuit against Capricor Therapeutics. With deadlines approaching and a legal team confident in their expertise, shareholders should evaluate their options carefully. As this litigation unfolds, investors remain hopeful for a resolution that restores not just financial losses, but also trust in the integrity of financial disclosures and corporate responsibility.

Individuals seeking further updates can visit Glancy's official website for additional information on the lawsuit and the ongoing advocacy efforts for impacted investors.